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ABSTRACT
Multiple-cycle high-dose therapy with autologous hematopoietic progenitor cell (AHPC) support has been used to
deliver dose-intensive therapy. We have used this approach as well as single-cycle high-dose therapy in tre a t i n g
patients with metastatic breast cancer. We present the outcomes of multiple-cycle high-dose therapies and compare
them with those resulting from single-course high-dose therapies perf o rmed at a single institution. Fifty-five
patients received 4 cycles of intensive chemotherapy with AHPC support. Three multicycle regimens were sequen-
tially applied. Twenty patients were enrolled to receive 4 cycles of high-dose mitoxantrone, thiotepa, and cyclophos-
phamide. Nineteen subsequent patients received this regimen modified by the incorporation of paclitaxel. Sixteen
patients received 2 cycles of high-dose melphalan, thiotepa, and paclitaxel and 2 cycles of mitoxantrone, thiotepa,
and paclitaxel. The results of all 3 multiple-cycle therapies are compared with those of 55 contemporaneous
patients with metastatic breast cancer who received a single course of high-dose cyclophosphamide and thiotepa or
cyclophosphamide, cisplatin, and BCNU (carmustine) with hematopoietic cell rescue. Multiple-cycle therapy was
associated with more infectious complications, increased transfusion re q u i rements, and increased hospital admis-
sions. However, there were no significant diff e rences in outcomes between the groups. For 55 patients who re c e i v e d
multiple-cycle therapy, the actuarial 3-year overall survival rate was 36% (95% confidence interval [CI] 23%-49%);
f reedom from pro g ression and event-free survival were both 15% (CI 5%-25%). The median time to disease pro-
g ression and median survival were 1.0 and 1.6 years, re s p e c t i v e l y. For the 55 patients who underwent a single course
of high-dose therapy, the 3-year overall survival was also 36% (CI 18%-54%), whereas freedom from pro g re s s i o n
and event-free survival were both 19% (CI 7%-31%). The median time to progression and median survival were
0.8 and 2.2 years, re s p e c t i v e l y. Within the constraints of this patient population, the outcomes of 4 cycles of high-
dose therapy with AHPC support were not superior to those resulting from single courses of high-dose therapy in
Biology of Blood and Marrow Transplantation 6:58-69 (2000)
©2000 American Society for Blood and Marrow Transplantation
Multiple-Cycle Therapy for Metastatic Breast Cancer
tation continues to re p resent an incurable condition, pro v i d-
ing justification for deferring cytotoxic treatment until ame-
lioration of symptoms becomes necessary.
To improve survival outcomes for such patients, high-
dose chemotherapy with autologous hematopoietic pro-
genitor cell (AHPC) support has been increasingly used to
t reat patients with metastatic breast cancer [8], resulting in 3-
year pro g re s s i o n - f ree survival rates of 15% to 20% [9]. Sur-
vival outcomes for patients who are able to achieve complete
remission at the time of high-dose therapy are re p o rt e d l y
b e t t e r, with 27% to 37% of women achieving 3-year pro-
g re s s i o n - f ree survival [7]. Given the more favorable risk/ben-
efit ratio for these patients, transplantation protocols have
re q u i red patients to achieve minimal disease (complete
remission or very good partial remission) before high-dose
t h e r a p y. This strategy usually entails early use of cytore d u c-
tive therapy when tumor volume is low and could account
for the improved survivals seen with high-dose therapy and
autografting [10]. Whether high-dose therapy will ultimately
p rolong survival after diagnosis of metastatic breast cancer
remains to be determined from prospective randomized tri-
als. Such trials must adequately stratify for patient risk fac-
tors and provide sufficient duration of follow-up evaluation.
Most high-dose therapy protocols have used a single
course of high-dose therapy with autograft support when
minimal disease is achieved after conventional cytore d u c t i v e
chemotherapy [7,9]. This approach provides peak doses of
d rugs for “consolidation” of the clinical response achieved
with conventional-dose treatment, but does not increase the
numbers of patients who become eligible for high-dose
therapy.
Another strategy to improve survival outcomes
involves augmentation of dose intensity with multiple
cycles of high-dose combination chemotherapy. Pre c l i n i c a l
data and tumor modeling have supported impro v e d
responses with therapies involving rapid administration of
chemotherapy [11,12], and clinical studies have under-
s c o red the importance of maximal conventional dosing and
scheduling in the achievement of event-free and overall
s u rvivals [13,14]. It is conceivable that both dose escalation
and efficient dose delivery could improve outcomes in the
setting of re c u rrent disease. Furt h e rm o re, an approach that
combines the two would not necessarily exclude patients
who could not achieve minimal disease with conventional
c y t o reduction or those with moderately bulky disease at
d i a g n o s i s .
Cloned growth factors, AHPC support, and impro v e-
ments in supportive care have allowed for chemotherapy
men in treating malignancies. Applying their methodology
to regimens used in the treatment of metastatic breast can-
cer, they observed statistically significant linear correlations
of SDI to overall response, complete remission (CR), and
median survival in 19 randomized trials comparing more
dose-intensive regimens with those administered at conven-
tional doses. Their results support the concept of dose
intensity in the treatment of metastatic breast cancer. I n
addition, they observed that a moderate increase in SDI was
n e c e s s a ry to demonstrate only a slight improvement in
median survival (eg, 0.5 SDI units correlated to 2 months).
This observation suggests that substantial increases in dose
intensity may be necessary to demonstrate statistically signifi-
cant improvements in survival. Since the drugs effective in
b reast cancer treatment generally cause myelosuppression as a
dose-limiting toxicity, the use of AHPCs to escalate doses of
multiple-cycle combination therapy administered in re l a t i v e l y
s h o rt intervals re p resents an attractive approach for the tre a t-
ment of patients with metastatic breast cancer.
Accordingly, we and others have implemented multiple-
cycle regimens supported with AHPCs and have demon-
strated the feasibility of this approach in treating a variety of
malignancies [20-27]. Our initially reported 4-cycle regimen
of mitoxantrone, thiotepa, and cyclophosphamide (MTC)
was subsequently modified twice to escalate drug delivery
and to ameliorate toxicity [21]. We hereby present our sin-
gle-institution results for all 3 multiple-cycle high-dose reg-
imens (n = 55) and compare them in a nonrandomized fash-
ion with those of contemporaneous patients (n = 55) who




One hundred ten female patients with re c u rrent or
newly diagnosed metastatic breast cancer were enrolled in
consecutive protocols using high-dose therapy with AHPC
support between November 1991 and November 1997. All
patients had been presented at a weekly new patient confer-
ence, at which time clinical data were reviewed and protocol
assignment was established. For all protocols, patient eligi-
bility criteria included age ≤65 years, Karnofsky perf o r-
mance status ≥80%, adequate organ function assessed by
pulmonary diffusion capacity of carbon monoxide at ≥60%
predicted, exercise left ventricular ejection fraction of ≥0.50,
HIV seronegativity, and no central nervous system metasta-
sis. The clinical protocols were approved and re v i e w e d
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Table 1. Pretreatment Patient Characteristics*
Multiple Cycle (n = 55) Single-Cycle (n = 55)
Median Age (Range) 44 (29-58) n (%) 46 (26-62) n (%) P value
Initial Diagnosis
Estrogen receptor (ER)+/reported ER status 34/51 (62) 29/46 (53)
Progesterone receptor (PR)+/reported PR status 32/49 (58) 24/41 (44)
Pre-/postmenopausal/unknown 51/2/2 46/5/4
Tumor size
T1 16 (29) 7 (13)
T2 22 (40) 20 (36)
T3 13 (24) 15 (27)
T4 1 (2) 4 (7)
Unknown 3 (5) 9 (16)
No. lymph nodes
0 13 (24) 15 (27)
1-3 12 (22) 14 (25)
4-9 11 (20) 10 (18)
10-19 10 (18) 6 (11)
≥20 5 (9) 6 (11)
Unknown 4 (7) 4 (7)
Prior adjuvant therapy
Radiation therapy 26 (48) 21 (38)
Hormonal therapy 22 (40) 14 (25)
Chemotherapy † Median 1 (0-2) Median 1 (0-2) .01 †
0 regimens 10 (18) 24 (44)
1 regimen 37 (67) 23 (42)
2 regimens 8 (15) 8 (15)
Metastatic disease
New diagnosis Stage IV disease 3 (5) 14 (25)
Disease-free interval (range) Median 27 mo (1-96) Median 24 mo (1-120) .78
Disease sites
Visceral 16 (29) 20 (36)
Bone 34 (62) 32 (58)
Soft tissue 36 (65) 38 (69)
Minimal disease 10 (18) 10 (18)
No. sites of disease Median 2 (1-5) Median 2 (1-7) .31
1 15 (27) 21 (38)
2 18 (33) 14 (28)
3 17 (31) 18 (33)
≥4 5 (9) 2 (4)
Radiation therapy for Met Ds 17 (31) 14 (25)
Hormonal therapy for Met Ds 16 (29) 18 (33)
Cytoreductive regimens † Median 1 (0-3) Median 1 (1-4) .0004 †
0 15 (27) 0 (0)
1 32 (58) 40 (73)
2 7 (13) 11 (20)
3 1 (2) 3 (5)
4 0 (0) 1 (2)
Total no. of prior regimens Median 2 (0-4) Median 2 (1-6) .27
0 1 (2)
1 17 (31) 15 (27)
2 27 (49) 25 (45)
3 9 (16) 13 (24)
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protocols did not receive cytoreductive therapy before treat-
ment. All 55 patients treated with single-cycle high-dose
therapy received 1 to 4 (median of 1) regimens of reinduc-
tion (cytoreductive) therapy at conventional dose. The
choice of therapy was based on prior treatment, and treat-
ment was administered by the primary referring oncologist.
Assessment of Patient Characteristics
Characteristics evaluated in the initial presentation of
b reast cancer used standard TNM staging criteria [28].
Patients who received surgical ovarian ablation were
assessed as having received hormonal therapy. In the evalua-
tion of metastatic disease, disease-free interval was defin e d
as the length of time between completion of primary ther-
apy and presentation of re c u rrent disease. The number of
sites involved by disease was evaluated as follows: disease to
any 1 organ, such as lungs, liver, or bone was scored as 1 site
each; disease to lymph node groups was scored by anatomic
site. For example, involvement of both cervical and medi-
astinal lymph node groups was scored as 2 sites. Pre t re a t-
ment patient characteristics are detailed in Table 1.
Study Design/Treatment Plan
Patients first underwent placement of a double-lumen
tunneled catheter. Fifty-five patients were enrolled to
receive 4-cycle high-dose therapy with AHPC support, as
represented schematically in Figure 1. This approach used a
single-agent “pulse” for mobilization of AHPCs followed by
4 cycles of combination therapy. During this study period,
3 multicycle regimens were sequentially developed. The
treatment regimens have been previously described in detail
[21,27]; their dosing and schedules are listed, with active
p rotocol dates, in Table 2. For mobilization of peripheral
blood progenitor cells, 38 patients received etoposide (VP-16)
2 g/m2 over 4 hours, and 15 patients received cyclophos-
phamide 4 g/m2 over 2 hours. Granulocyte-colony stimulat-
ing factor (G-CSF) at approximately 10 µg/kg per day was
a d m i n i s t e red 24 hours after chemotherapy and continued
daily until the target number of mononuclear cells or
CD34+ cells was collected by apheresis. Two patients did not
receive VP-16 or cyclophosphamide because AHPCs were
p reviously collected by G-CSF alone. The AHPCs were
p rocessed and cry o p re s e rved as described previously [21].
Purging techniques were not used.
Twenty patients were enrolled in the first multicycle pro-
tocol using 4 cycles of high-dose MTC delivered every 28
days. MTC therapy with AHPC infusion was administere d
in hospital for the first 5 patients. Subsequent patients were
tient setting. Nineteen subsequent patients were enrolled to
a modification of the protocol using the same drugs but with
dose intensification of thiotepa and the incorporation of
paclitaxel into the treatment schema (MTTC × 4). This pro-
tocol was amended to deliver 4 cycles of therapy every 21
days. Patients received MTTC therapy and AHPCs in the
outpatient setting. The last group of 16 patients enrolled to
multiple-cycle therapy received 2 cycles of high-dose mel-
phalan, thiotepa, and paclitaxel, and 2 cycles of mitox-
a n t rone, thiotepa, and paclitaxel (ATT × 2/MTT × 2) deliv-
e red in 21-day intervals and supported with AHPCs [27].
Fifty-five patients received a single course of high-dose
therapy with G-CSF–mobilized AHPC support. Two estab-
lished regimens were sequentially used. Eleven patients
received high-dose cyclophosphamide and thiotepa (CT)
[29] and 44 subsequent patients received high-dose cyclophos-
phamide, cisplatin, and BCNU (CPB or STAMP I) [30].
The patients who received CT and the initial 4 p a t i e n t s
who received CPB received high-dose therapy with AHPC
infusion and remained hospitalized until myeloid graft re c o v-
e ry. Subsequent patients who received CPB were discharg e d
on post-transplantation day +1 if symptoms could be con-
t rolled with outpatient treatment and if clinically stable.
These regimens are also listed in Table 2.
S u p p o rt i v e Care and Response Assessment
P rophylactic antibiotics, transfusion support, G-CSF
administration, and continuous bladder irrigation were
instituted according to the current institutional standard at
the time of protocol enrollment [21,27,29-32].
Toxicity monitoring was graded using the Southwest
Oncology Group common toxicity criteria. Patients were
removed from the trial for any grade III-IV nonhematologic
toxicity or for refractory or progressive disease.
Breast cancer lesions were assessed by physical examina-
tion and imaging studies at the start of high-dose therapy.
CR, partial response (PR), and very good partial re s p o n s e
(VGPR) were defined by standard criteria: disappearance of
all measurable tumor, >90% reduction in measurable
lesions, and >50% reduction in the product of the bidimen-
sional measurements, re s p e c t i v e l y, for 4 weeks duration.
Definitions for minimal response, stable disease, and pro-
g ressive disease included <50% reduction in disease, no
change in tumor measurements, and >25% increase in
tumor size or the appearance of new lesions, respectively.
Treatment After Recov e r y From High-Dose Therapy
After re c o v e ry from autografting, patients with tumors
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sites of bony or soft tissue disease was initiated 6 to 8 weeks
after recovery from high-dose therapy.
Statistical Anal y s i s
P ro g re s s i o n - f ree intervals and survivals were measure d
f rom the day of first autograft infusion until disease pro g re s-
sion or death. Descriptive statistics are re p o rted as fre q u e n-
cies and medians. The method of Mann-Whitney rank sum
testing was used to determine diff e rences in median values.
P e a r s o n ’s chi-square method was used to test diff e rences in
distribution of disease status at time of high-dose therapy.
E v e n t - f ree, pro g re s s i o n - f ree, and overall survival curves were
calculated by means of the Kaplan-Meier pro d u c t - l i m i t
of high-dose therapy. The group of patients who re c e i v e d
multiple-cycle and single-course high-dose therapy had sim-
ilar characteristics, including disease-free intervals, median
number of sites of disease, numbers of patients who had
bone and soft tissue disease, and median number of total
prior regimens received by the time of high-dose therapy.
Equal numbers of patients had minimal disease at the time
of metastatic presentation. Prior anthracycline therapy was
a d m i n i s t e red to 47 patients who received multicycle re g i-
mens and to 44 patients who received single-cycle therapy.
Characteristics resulting in significant statistical diff e r-
ences in distribution between the 2 groups include number
of initial adjuvant regimens and number of cytore d u c t i v e
Table 2. High-Dose Chemotherapy Regimens*
Day No. of Patients Total Regimen Dose
Four-Cycle HDC Regimens
VP-16 Mobilization 2 g/m 2 20
1. MTC 3 4 (February 1992-May 1993)
Mitoxantrone 6 mg/m 2 CI 3 3 d 25,24,23 72 mg/m 2
Thiotepa 50 mg/m 2 CI 3 2-3 d 25,24, 23 400-600 mg/m 2
Cyclophosphamide 1.5-1.65 g/m 2 3 3 d 25,24,23 18-19.8 g/m 2
2. MTTC 3 4 (June 1993-December 1994) 19
Mitoxantrone 9 mg/m 2 CI 3 2 d 24,23 72 mg/m 2
Thiotepa 100 mg/m 2 CI 3 2 d 24, 23 800 mg/m 2
Cyclophosphamide 2.25 g/m 2 3 2 d 24, 23 18 g/m 2
Paclitaxel 100-150 mg/m 2 3 1 22 400-600 mg/m 2
3. Cyclophosphamide Mobilization 4 g/m 2
ATT 3 2/MTT 3 2 (December 1994-June 1996)
Melphalan 80 mg/m 2 3 1 24 16 160 mg/m 2
Thiotepa 150 mg/m 2 3 2 d CI 24, 23 1200 mg/m 2
Paclitaxel 200 mg/m 2 3 1 22 800 mg/m 2
Mitoxantrone 15 mg/m 2 3 2 d CI 24, 23 60 mg/m 2
Thiotepa 150 mg/m 2 3 2 d CI 24,23
Paclitaxel 200 mg/m 2 3 1 22
Single-Course Regimens
1. CT (November 1991-November 1994)
Cyclophosphamide 1.5 g/m 2 3 4 d CI 26 to 23 11 6 g/m 2†
Thiotepa 200 mg/m 2 3 4 d CI 26 to 23 800 mg/m 2
2. CPB (February 1995-November 1997)
Cyclophosphamide 1.875 g/m 2 3 3 d 25,24, 23 44 5625 mg/m 2†
Cisplatin 55 mg/m 2 3 3 d CI 25,24,23 165 mg/m 2
BCNU 600 mg/m 2 3 1 22 600 mg/m 2
*ATT/MTT indicates melphalan, thiotepa, and paclitaxel/mitoxantrone, thiotepa, and paclitaxel; BCNU, carmustine; CI, continuous infusion; HDC, high-dose
chemotherapy; CPB, cyclophosphamide, cisplatin, and BCNU; CT, cyclophosphamide and thiotepa; MTC, mitoxantrone, thiotepa, and cyclophosphamide; MTTC,
MTC with dose intensification of thiotepa and addition of paclitaxel.
†As previously reported in references 29 and 30.
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mononuclear cells per kilogram per cycle. Two initial
patients enrolled in multicycle therapy received MTC with
G-CSF alone to d e t e rmine whether bone marrow re c o v e ry
could be achieved without AHPC support. Both patients
required AHPC infusion 15 to 16 days after completion of
chemotherapy because of persistent profound neutro p e n i a
(absolute neutrophil count [ANC] <1 0 0 /µL), after which
ANC re c o v e ry to ≥5 0 0 /µL re q u i red another 8 days. All
subsequent patients received AHPC support. The dose of
AHPCs administered at each cycle of therapy and the
median re c o v e ry of ANC ≥5 0 0 /µL and platelet counts
≥ 2 0 , 0 0 0 /µL have been described in detail for MTC and
ATT/MTT [21]. For patients who received MTTC, the
median times to ANC and plate let  re c o v e ry were 9
(range 8-14) and 10 (range 7-48) days, respectively.
Patients treated with single-cycle therapy were re c o n s t i-
tuted with AHPCs at a dose range of 0.95 to 21.2 3
1 08 mononuclear cells/kg. The median times to ANC and
platelet recovery for patients who received CT were 10 and
13 days, re s p e c t i v e l y. For patients who received CPB, the
median CD34+ cell dose was 5.1 3 106/kg (range 1.5-9.1 3
106/kg), which resulted in median days to ANC and platelet
recovery of 9 and 10.5, respectively.
Tr a n s f u s i o n s
The total numbers of transfusion products required per
patient enrolled to each protocol are delineated in Table 4.
The number of transfusions for patients who received mul-
tiple-cycle therapy include blood products re q u i red during
apheresis after mobilization chemotherapy as well as during
recovery from each cycle of combination high-dose therapy.
The fewer numbers of red cell and platelet pro d u c t s
required for patients who received CPB single-course ther-
apy reflect the designation of CD34+ cells rather than
MTTC regimen, whereas the toxicities associated with
ATT/MTT are notable for infectious complications and a
lack of significant effect on organ function. The single-
course regimen toxicities with CPB are predominantly due
to the well-known effect of interstitial pneumonitis associ-
ated with BCNU [34,35].
S u r vival Data
The median follow-up is 2 years in the single-cycle
g roup compared with 1.8 years in the multicycle gro u p .
There was no significant difference in overall survival, free-
dom from pro g ression, or event-free survival between the
g roup of patients who received multiple-cycle high-dose
therapy and those who received single-course high-dose
t h e r a p y. Figure 2 illustrates the Kaplan-Meier surv i v a l
curves comparing the outcomes of multicycle treatment and
single-cycle treatment. For all 55 patients enrolled in multi-
ple-cycle therapy, the actuarial 3-year overall survival was
36% (95% confidence interval [CI] 23%-49%), and fre e-
dom from pro g ression and event-free survival were both
15% (CI 5%-25%). The median time to disease progression
and median s u rvival  were 1 .0 and 1.6  years, re s p e c-
t i v e l y. For the 55 patients who received single-course
high-dose therapy, the 3-year overall survival was also 36%
Table 4. Number of Tranfusion Products per Patient*
No. PRBC Transfusions No. Plt Transfusions
Median (Range) Median (Range)
Multicycle Regimen
MTC 17.5 (5-38) 6 (2-29)
MTTC 21 (4-35) 11 (3-40)
Table 3. Delivery of Multiple-Cycle Therapy*
No. Cycles Intervals Between Cycles (Median No. of Days)
Delivered/No. Mobilization to Dt (Cycle 1 to 2) Dt (Cycle 2 to 3) Dt (Cycle 3 to 4)
Regimens Possible Cycles (%) Cycle 1 (Range) (Range) (Range) (Range)
MTC 72/80 90 25 (18-49) 28 (23-58) 29 (25-56) 28 (21-47)
MTTC 69/76 91 17 (13-47) 21 (20-35) 24 (21-46) 28 (21-39)
ATT/MTT 52/64 81 23 (20-52) 23 (21-42) 25 (21-45) 25 (21-45)
*ATT/MTT indicates melphalan, thiotepa, and paclitaxel/mitoxantrone, thiotepa, and paclitaxel; MTC, mitoxantrone, thiotepa, and cyclophosphamide; MTTC,
MTC with dose intensification of thiotepa and addition of paclitaxel; Dt (cycle 1 to 2), time interval from 1 cycle to another of multicycle therapy.
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(CI 18%-54%) while freedom from progression and event-
f ree survival were both 19% (CI 7%-31%). The median
time to disease progression and median survival was 0.8 and
t h e r a p y. The median follow-up is 3.1 years for multicycle
patients and 2 years for single-cycle patients. Outcome
analysis of this subset for 3-year overall survival was 54%
Table 5. Toxicities of High-Dose Therapy*
Multiple-Cycle Regimens Single-Course Regimens
MTC (No. Cycles) MTTC ATT/MTT Total CT CPB Total
Toxicities (No. of Episodes) VP-16 (19) (72) VP-16 (19) (69) CY (15) (52) Episodes (11) (44) Episodes
Fever (no source) 10 20 1 15 2 7 55 2 9 11
GI toxicity 11 1 12 3 4 7
TPN 2 1 1 4 1 2 3
Pancreatitis 1 1
Hemorrhagic cystitis 2 2 5 9 2 2
Hospital admissions 2 37 2 23 3 18 85 11 † 5 16
Overnight observations 7 7
Congestive heart failure 1 4 5 2 2
Veno-occlusive disease of liver 1 2 3 1 1
Diffuse alveolar hemorrhage 2 2
Interstitial pneumonitis 1 5 2 6 1 24 25
Idiopathic thrombocytopenic purpura 1 1 1 1
Hemolytic uremic syndrome 1 1
Mortality 0 1 1 2 2 2
Bacteremia
Gram-pos organisms 2 5 7 1 1
Gram-neg organisms 4 2 4 4 14
Fungemia 3 1 4 2 2
Viral reactivation (HSV, VZV) 1 9 6 5 21 5 5
Pneumonia
Bacterial 2 2 1 1 2
Fungal 2 2
Viral (RSV, CMV) 1 1 2
Pneumocystis carinii 1 1
Miscellaneous
Cellulitis: Xanthomonas 1 1
Catheter-related 1 1 2
Clostridium difficile enterocolitis 1 3 4
Exudative pharyngitis 2 2
Sinusitis 1 1
Pilonidal cyst 1 1
Perirectal abscess 1 1
Urinary candidiasis 2 2
*ATT/MTT indicates melphalan, thiotepa, and paclitaxel/mitoxantrone, thiotepa, and paclitaxel; CPB, cyclophosphamide, cisplatin, and BCNU; CMV,
cytomegalovirus; CT, cyclophosphamide and thiotepa; Cy, cyclophosphamide; GI, gastrointestinal; HSV, herpes simplex virus; MTC, mitoxantrone, thiotepa, and
cyclophosphamide; MTTC, MTC with dose intensification of thiotepa and addition of paclitaxel; RSV, respiratory syncytial virus; TPN, total parenteral nutrition;
VZV, varicella zoster virus.
†All patients hospitalized until autograft recovery.
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statistically inferior to the 13 patients who had achieved CR
or VGPR (P = .001, P = .002, P = .039, respectively).
For patients who did not achieve CR or VGPR, there
w e re no signficant diff e rences in survival between the
2 treatment groups.
DISCUSSION
The feasibility of delivering 4 cycles of high-dose therapy
with AHPC support has been previously re p o rted for MTC
[21] and ATT/MTT [27] as well as for other re g i m e n s
[25,26,36,37]. As with conventional dose combinations, com-
parison of a re g i m e n ’s dose intensity with that of another has
been problematic. However, a single score for a particular re g-
imen can be calculated by applying the SDI method re p o rt e d
delayed in subsequent cycles because of the development of
o rgan toxicities (hemorrhagic cystitis, pneumonitis, card i a c
dysfunction) or infections (Table 5). Nevertheless, 91% of
intended cycles were delivered with multiple delays. The
ATT/MTT regimen was slightly less dose-intensive com-
p a red with MTTC and appeared to be more feasible,
although only 81% of intended cycles were delivered. Fewer
re g i m e n - related toxicities occurred; however, infectious
complications continued to be prevalent [27].
As reflected by the multiple exposures to high-dose
therapy and resultant episodes of pancytopenia, more
episodes of life-threatening organ toxicities and a range of
infectious complications occurred in the group of patients
who received multiple-cycle therapy. These patients also
re q u i red readmissions more frequently and received more
Table 6. Regimen Dose Intensity and Calculation of Summation Dose Intensity*
Conventional Protocol Total Protocol Protocol Unit Dose Fractional
Chemotherapy Dose Dose Dose Dose Intensity (DI) Intensity (UDI) UDI
Drug (mg/m 2 per cycle) (mg/m 2 per cycle) (mg/m 2) (mg/m 2 per wk) (mg/m 2 per wk) (DI/UDI)
MTC Protocol (q 28 d over 16 wk)
VP-16 2000 667 340 1.96
Mitoxantrone 12-14 18 72 4.5 5 0.9
Thiotepa 20-50 150-200 600-800 (37.5 to) 50 58 † 0.86
Cyclophosphamide 1400 4500-5000 18,000-20,000 (1125 to) 1250 650 1.92
Weighted SDI ‡ = 3.41
MTTC Protocol (q 21 d over 12 wk)
VP-16 2000 667 340 1.96
Mitoxantrone 12-14 18 72 6 5 1.2
Thiotepa 20-50 200 800 66.7 58 1.15
Paclitaxel 135-175 100-150 400-600 (33 to) 50 50 1.0
Cyclophosphamide 1400 4500 18,000 1500 650 2.3
Weighted SDI = 4.91
ATT/MTT Protocol (q 21 d over 12 wk)
Cyclophosphamide 4000 1333 650 2.05
Melphalan 25-40 80 160 13.3 9 1.47
Mitoxantrone 12-14 30 60 10 5 2.0
Thiotepa 20-50 300 1200 100 58 1.72
Paclitaxel 135-175 200 800 66.7 50 1.33
Weighted SDI = 4.24
*ATT/MTT indicates melphaln, thiotepa, and paclitaxel/mitoxantrone, thiotepa, and paclitaxel; MTC, mitoxantrone, thiotepa, and cyclophosphamide; MTTC,
MTC with dose intensification of thiotepa and addition of paclitaxel; SDI, summation dose intensity; VP-16, etoposide.
†Thiotepa UDI (Hryniuk, personal communication).
‡Weighted average SDI calculated by contribution of initial single-agent mobilization followed 3 weeks later by combination chemotherapy. Sample calculation of
weighted SDI: (1.96)(3 weeks) + (0.9 + 0.86 + 1.92)(16 weeks)/19 weeks = 3.41.
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tus at time of high-dose therapy. Because response to
c y t o reductive therapy and outcomes for patients with
metastatic breast cancer are significantly influenced by prior
t h e r a p y, meaningful interpretation of survival data may be
constrained owing to these diff e rences in distribution
between the patient groups and the relatively limited num-
ber of patients evaluable in subset analyses.
For all patients, there are no significant diff e rences in
e v e n t - f ree survival, freedom from pro g ression, and overall
s u rvival between the 2 treatment approaches. Six patients
enrolled in multicycle treatment received 2 or fewer cycles
of high-dose therapy. The survival outcomes of the remain-
ing 49 patients who received 3 or 4 cycles of therapy are
similar to those of patients who received single-cycle ther-
apy. Therefore, the majority of patients enrolled to multicy-
cle therapy received adequate numbers of high-dose cycles
to allow for evaluation of outcomes.
The 13 patients who achieved a CR or VGPR before
multicycle high-dose therapy may have had a trend toward
superior freedom from pro g ression (P = .13). A review of
the pre t reatment characteristics of these patients suggests
that this group had features predicting more favorable out-
comes, including metastatic disease at 1 or 2 sites, and 1 to 2
prior chemotherapy regimens before high-dose therapy.
The median freedom from disease pro g ression for this
g roup was 2.3 years, compared with 0.9 years for the 31
patients who received single autografts and demonstrated
m o re heterogenous risk features. Nevertheless, the over-
all survival between the 2 groups was similar, with only a
2-month improvement in the multicycle gro u p .
It is conceivable that if the 2 treatment arms were bal-
anced with regard to CR/VGPR status, there may have been
a statistical difference in FFP and EFS. Because both groups
were relatively balanced in the number of total prior thera-
pies received, it is unclear whether the differences in num-
bers of adjuvant therapies or cytoreductive therapies could
have a significant impact on outcomes. The similar overall
s u rvival between the 2 groups could also be accounted for
by the possible use of salvage therapies, including hormonal
and immune-based therapies in patients who suff e re d
relapse after single-cycle high-dose therapy which may not
have been feasible for patients with more toxicity who suf-
fered relapse after multicycle therapy.
The results of other multiple-cycle high-dose re g i-
mens in the treatment of patients with metastatic bre a s t
cancer have been previously reviewed [38,39]. Diff e re n t
sequences of single-agent and combination regimens and
v a rying numbers of cycles of therapy preclude adequate
tamoxifen, and the surprisingly poor survivals re s u l t i n g
f rom “conventional” tre a t m e n t .
In reviewing the relative dose intensity of conventional
chemotherapy regimens, Hryniuk et al. [19] found that the
highest S D I originated from a study by Hortobagyi et al. [43],
whose high-dose FA C regimen yielded an SDI value of 3.24,
slightly lower than our M T C regimen SDI of 3.41, suggest-
ing that chemotherapy dose intensity for certain drugs may
be escalated sufficiently without the need for AHPC support .
U n f o rt u n a t e l y, the SDI model presumes equal efficacy fro m
later and earlier cycles of therapy and cannot address the eff e c t s
of peak doses of high-dose chemotherapy administered as con-
solidation after achievement of CR or V G P R as perf o rm e d
with single autografting. Our data also indicate that multiple-
cycle high-dose regimens do not appear to benefit patients
who cannot achieve CR or V G P R with conventional therapy.
A single course of h i g h - d o s e therapy can provide peak
doses of drug rather than dose-intensive drug delivery.
P re s u m a b l y, decreasing the number of cycles of high-dose
therapy may allow for increases in peak drug dosing. Nev-
e rtheless, it is unclear whether double [22,42,44-49] or
triple [ 2 0 , 2 4 , 5 0 , 5 1 ] cycles of h i g h - d o s e therapy will re s u l t
in improved outcomes for patients with re c u rre nt disease,
although the efficacy of such therapies would need to be
substantially superior to single autografts to justify the
potential pro b l e m s associated with multiple-cycle t h e r a p y.
“High-dose sequential” [52-54] and “dose dense” [55]
chemotherapy approaches using single agents at high dose
appear to yield promising results in the high-risk disease
setting, but may be disappointing for re c u rrent disease due
to greater tumor heterogeneity and drug resistance [56,57].
High-dose therapy with AHPC support offers signifi-
cant tumor cytoreductive potential and may benefit patients
who achieve minimal disease before autografting. Neverthe-
less, emphasis should be placed on the viewpoint of trans-
plantation technologies as part of multimodality tre a t m e n t
of malignant disease, rather than as an end therapy in itself,
particularly in the setting of recurrent disease.
In summary, 4-cycle high-dose combination therapy
s u p p o rted with AHPCs is feasible, but is associated with a
p rolonged period of treatment, many episodes of pancy-
topenia requiring more transfusion support, and a range of
re g i m e n - related toxicities and infectious complications.
Within the constraints of this patient population, the out-
comes of such an approach are no diff e rent from those
resulting from a single course of high-dose therapy in the
t reatment of metastatic breast cancer. Other strategies are
clearly needed to treat this challenging disease.
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